GlobeNewswire·Nov 5, 2026, 8:30 AM ET

Dogwood Therapeutics Announces Third Quarter 2026 Financial Results

Dogwood Therapeutics completed the Halneuron Phase 2b trial for chemotherapy-induced neuropathy, with top-line results expected in November 2026.
The Phase 2b long-term extension study fully recruited 95 patients to assess pain reduction over three months, with completion anticipated in early 2027.
The company closed a $5 million private placement with Sealbond Limited, a subsidiary of CK Life Sciences Int'l., to fund Phase 3 preparations, working capital, & general corporate purposes.
Combined cash on hand of $4.9 million & the $5 million private placement provides an operational runway through the first quarter of 2027.
Third quarter 2026 revenue was $0.1 million from licensing payments, while research & development expenses decreased to $3.3 million from $14.5 million in the prior year period.
General & administrative expenses for the third quarter of 2026 rose to $1.6 million, driven by increased personnel costs.
Net loss attributable to common stockholders for the third quarter of 2026 was $4.9 million, or $0.14 per share, compared to $15.7 million in the same period of 2025.
Halneuron received FDA fast track designation for treating CINP, while the SP16 IV Phase 1b trial remains fully funded by the National Cancer Institute.